Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patil, Ajit Subhash
- To Study the Effect of Intravenous Tranexamic Acid on Blood Loss During and After Caesarean Section
Abstract Views :334 |
PDF Views:123
Authors
Affiliations
1 Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, IN
1 Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, IN
Source
MVP Journal of Medical Sciences, Vol 6, No 1 (2019), Pagination: 93-99Abstract
Introduction: Incidence of postpartum haemorrhage is 6.4% in caesarean section. WHO guidelines for prevention of PPH include oxytocin as first line drug. Intravenous tranexamic acid has been used to reduce hemorrhage during surgical procedures. In this study use of tranexamic acid on blood loss during and after Lower Segment Caesarean Section (LSCS) was evaluated. Aims and Objectives: 1. To study the efficacy of tranexamic acid in reducing blood loss during and after lower segment caesarean section, and 2. To study any side effect on neonate. Materials and Methods: A randomized prospective observational study of 100 patients were conducted. Patients were divided into: Group (A group) had received 1 gm tranexamic acid intravenous 20 minutes before skin incision + 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Group (B group) received only 20 units oxytocin drip in 500ml Ringer Lactate after delivery of baby. Patient’s blood loss was measured (intra operative, post placental and post-operative period) by weighing dry and soaked mops and separate suction bottle for blood. Results: Statistically significant difference (P < 0.001) in the quantity of blood loss was observed. In group A total blood loss during LSCS was 476.49 ml while in group B it was 576.06 ml. Intra operative blood loss in group A was 455.63 ml while in group B it was 536.53 ml. Post placental blood loss in group A was 411.59 ml while in group B was 485.08 ml. Not a single neonate had poor APGAR score and no NICU admission was required. Conclusion: Use of tranexamic acid with oxytocin significantly decreased blood loss during and after caesarean section without any side effect on neonate.Keywords
Lower Segment Caesarean Section (LSCS), Oxytocin, Post-Partum Haemorrhage, Tranexamic Acid.References
- Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC. Postpartum hemorrhage after caesarean delivery: An analysis of risk factors, South Med. J. 2005; 98:681-685. https://doi.org/10.1097/01.SMJ.0000163309.53317.B8, https://doi.org/10.1097/01.SMJ.0000152760.34443.86.
- Who statement on caesarean section rates. Geneva: World health organization, 2015 (WHO/RHR/15.02).
- World Health Organization. The Prevention and Management of Postpartum Haemorrhage. Report of a Technical Working Group, Geneva, 3-6 July, 1989. Unpublished document. WHO/MCH/90.7. Geneva: World Health Organization 1990.
- Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid, Biochimicaet Biophysica Acta (BBA)-General Subjects. 1981; 673:75-85. https://doi.org/10.1016/0304-4165(81)90312-3.
- Satyavathi K, Vemu NJ, Mohammed S. Tranexamic acid: A proven antifibrinolytic agent (A review), Oriental Journal of Chemistry. 2009; 25(4):987-992.
- Pfanner G, Kilgert K. Hemorrhagic complications in obstetrics, Hamostaseologie. 2006; 26(3 Suppl 1):S56-63. [Article in German]. https://doi.org/10.1055/s-0037-1617083.
- Levy JH, Dutton RP, Hemphill JC, Shander A, Cooper D, Paidas MJ, et al. Hemostasis summit participants: Multidisciplinary approach to the challenge of hemostasis, Anesth Analg. 2010; 110:354-364. https://doi.org/10.1213/ANE.0b013e3181c84ba5. PMid: 20007735.
- Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion, Cochrane Database Syst. Rev. 2007; 4:CD001886. https://doi.org/10.1002/14651858.CD001886.pub2.
- CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH2): A randomised, placebo controlled trial, Lancet. 2010; 376:23-32. https://doi.org/10.1016/S0140-6736(10)6083-55.
- Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: A multi-center, randomized trial, Eur J. Obstet. Gynecol. Reprod. Biol. 2004 Feb 10; 112(2):154-157. https://doi.org/10.1016/S0301-2115(03)00287-2.
- Gohel Mayur, Patel Purvi, Gupta Ashoo, Desai Pankaj. Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: A randomized case controlled prospective study, The J. of Obstet. Gynecol. of India. May/ June 2007; 57(3):227-230
- Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD. Efficacy of tranexamic acid in reducing blood loss after caesarean section, Matern Fetal Neonatal Med. 2009 Jan; 22(1):9-5. https://doi.org/10.1080/14767050802353580. PMid: 19165682.
- Estimation of Level of Serum Lactate Dehydrogenase in Pre-Eclampsia Patients and its Association with Maternal and Fetal Outcome
Abstract Views :304 |
PDF Views:109
Authors
Affiliations
1 PG Resident, Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Center, Nashik - 422003, Maharashtra, IN
2 Associate Professor, Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Center, Nashik - 422003, Maharashtra, IN
1 PG Resident, Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Center, Nashik - 422003, Maharashtra, IN
2 Associate Professor, Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College, Hospital and Research Center, Nashik - 422003, Maharashtra, IN
Source
MVP Journal of Medical Sciences, Vol 6, No 2 (2019), Pagination: 177-182Abstract
Introduction: Pre-eclampsia is a pregnancy-specific syndrome recognised as a leading cause of maternal and perinatal mortality. Etiopathogenesis of preeclampsia is defective placentation and endothelial dysfunction leading to oxidative stress and cellular lysis. Lactate Dehydrogenase (LDH) is an intracellular enzyme of glycolysis. Hypoxia and cellular lysis results in elevated levels of LDH. Early detection and management are important in prevention of Preeclampsia complications and deaths. Hence, the present study was conducted to estimate levels of Sr. LDH in Pre-eclampsia patients to find its association with maternal and fetal outcome was undertaken. Materials and Methods: Present prospective study was conducted in Department of Obstetrics and Gynaecology from August 2016 to December 2018 consisting of 84 cases of preeclampsia of ≥28 weeks gestation divided in 2 groups; Mild and Severe Preeclampsia. Sr. LDH was estimated in all study participants and its association with parameters of maternal and fetal outcome was observed. Results: In the present study, 46 patients had Mild Preeclampsia. and 38 had Severe Preeclampsia. Most cases of Mild preeclampsia. i.e., 78.3% had LDH <600 IU/L whereas 71.1% of Severe Preeclampsia. had LDH >600 IU/L. Complications like eclampsia in 66.7%, HELLP in 33.3%, Abruptio placenta in 55.6%, ARF and DIC in 33.3% cases were noted more in patients with LDH >800 IU/L. Fetal still birth in 55.6%, Lower APGAR score and more NICU admission and Early neonatal death was present in babies of preeclampsia mother with LDH >800 IU/L. There was found statistically significant association (p<0.001) of raised Sr. LDH levels with poor maternal and fetal outcome in preeclampsia patients. Conclusion: Elevated levels of Sr. LDH during hypoxia, indicate the cellular damage and dysfunction occurring in preeclampsia. Detection of patients with increased levels of LDH is of crucial importance to detect and promptly manage the complicated cases and decrease the morbidity and mortality in mother and fetus.Keywords
Fetal Outcome, Lactate Dehydrogenase, Maternal Outcome, Pre-Eclampsia.References
- Chesley LC. Hypertensive disorders or pregnancy. New York, NY, USA: Appleton-Century-Crofts, 1978. 4th ed. 2015; 25–36.
- Barret M. Schroeder. Hypertension in Pregnancy, American College of Obstetricians and Gynecologist, Obstet Gynecol 2013; 122: 1122–31. https://doi.org/10.1097/01 AOG.0000437382.03963.88.
- F. Gary Cunningham, Kenneth J. Leveno, Steven L. Bloom, John C. Hauth, Dwight J. Rouse, Catherine Y. Spong. Williams Obstetrics-23rd ed. New York, NY: McGraw-Hill; 2010: 706–756.
- Redman CW, Sargent IL, Taylor RN: Immunology of abnormal pregnancy and preeclampsia. In Taylor RN, Roberts JM, Cunningham FG (eds): Chesley’s Hypertensive Disorders in Pregnancy, 4th ed. Amsterdam, Academic Press, 2014. https://doi.org/10.1016/B978-0-12-407866-6.00008-0.
- Davidge S, de Gischolar_main C, Taylor RN: Endothelial cell dysfunction and oxidative stress. In Taylor RN, Roberts JM, Cunningham FG (eds): Chesley’s Hypertensive Disorders in Pregnancy, 4th ed. Amsterdam, Academic Press, 2014.
- Burd LI, Simmons MA, Makowski EL, et al. Placental production and foetal utilization of lactate and pyruvate. Nature. 1975; 254: 710–1. https://doi.org/10.1038/254710a0.
- Kay HH, Zhu S, Tsoi S. Hypoxia and lactate production in trophoblast cells. Placenta. 2007; 28(8-9): 854–60. https://doi.org/10.1016/j.placenta.2006.11.011.
- Saxena N, Bava AM, Nandanwar Y. Maternal and perinatal outcome in severe preeclampsia. Int J Reprod Contracept Obstet Gynecol 2016; 2171–6. https://doi.org/10.18203/2320-1770.ijrcog20162086.
- Wroblewski F, Ladue J. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955; 90(1): 210-3. https://doi.org/10.3181/00379727-90-21985.
- Qublan HS, Amarun V, Bateinen O, et al. LDH as biochemical marker of adverse pregnancy outcome in severe preeclampsia. Med Sci Monit. 2005; 11: 393–7.
- Jaiswar SP, Gupta A, Sachan R, Natu SN, Shaili M, Lactic dehydrogenase: A biochemical marker for PreeclampsiaEclampsia. J Obst Gyn Ind (Nov-Dec 2011); 61(6): 645–648. https://doi.org/10.1007/s13224-011-0093-9.
- Vinitha PM, Chellatamizh M, Padmanaban S. Role of serum LDH in preeclampsia as a prognostic factor – a cross sectional case control study in tertiary care hospital. Int J Reprod Contracept Obstet Gynecol. 2017; 6: 595–8. https://doi.org/10.18203/2320-1770.ijrcog20170389.
- Umastyasri Y, Vani I, Samita P, Role of LDH (lactate dehydrogenase) in preeclampsia- eclampsia as a prognostic marker: An Observational study. IAIM, 2015; 2(9): 88–93.
- Urvashi S, Hariharan, C. Maternal outcome in PIH Patients in Relation with Serum LDH Levels. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). Jan 2017; 16(1) Ver. VIII: 01-04. https://doi.org/10.9790/0853-1601080104 e-ISSN: 2279–0853, p-ISSN: 2279–0861.
- Mahalakshmi, N. K. Lactate dehydrogenase a biochemical marker in assessing the severity of preeclampsia. Int J Curr Res., 2017; 9(04): 49334–49336.